Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafinlar and Mekinist for BRAF Mutated Ameloblastoma
NCT02367859Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jul 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in ameloblastoma, sponsored by Stanford University. Primary endpoint: Objective Response Rate at 6 weeks. Started Jul 2017; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
ameloblastoma
Beyond the preview
Go deeper on NCT02367859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367859.